

**Drug Development:  
A Translational Approach  
From Molecule to Man**

**April 24, 2006**

**Tuition**

The tuition fee for the conference is \$750.00. If you are a Resident or Fellow-in-Training the tuition fee is \$100.00 (with letter of verification from department chair).

**Registration Information**

To register for the conference and/or book hotel and flight accommodations, log on to [www.goldreg.com/development](http://www.goldreg.com/development).

For more information, please contact: *Travel Destinations* at 410-363-3111 or email [development@traveldest.com](mailto:development@traveldest.com).

**Other Information**

For more information on the Department of Psychiatry at the Massachusetts General Hospital and the Depression Clinical & Research Program, please visit the following websites:

[www.massgeneral.org/allpsych](http://www.massgeneral.org/allpsych)  
[www.massgeneral.org/depression](http://www.massgeneral.org/depression)

**Simches Research Building  
Massachusetts General Hospital  
175 Cambridge Street  
Boston, MA 02114**

**Drug Development: A Translational Approach From Molecule to Man  
A Conference Focusing on The Development of New Antidepressants**



**Drug Development:  
A Translational Approach  
From Molecule to Man**

**A Conference Focusing  
on The Development of  
New Antidepressants**

**Monday April 24th, 2006**

**Simches Conference Room #3110  
Simches Research Building  
Massachusetts General Hospital  
175 Cambridge Street  
Boston, MA 02114**

**Featuring:**

**William A. Carlezon, PhD  
Earl Giller, MD, PhD  
William Potter, MD, PhD**



MASSACHUSETTS GENERAL HOSPITAL  
Department of Psychiatry



DEPRESSION CLINICAL & RESEARCH PROGRAM

**Drug Development:  
A Translational Approach  
From Molecule to Man**

Simches Conference Room #3110  
Simches Research Building  
Massachusetts General Hospital  
175 Cambridge Street  
Boston, MA 02114

**April 24th, 2006**

**Introduction**

Major Depressive Disorder is a highly prevalent and disabling condition. The development of new antidepressants over the past decade has been challenged by a lack of relevant animal models for depression, clear molecular targets, methodological and measurement issues, and a progressive increase in placebo response rates. This conference will examine some of these key issues in CNS drug development and describe innovative solutions to existing problems. In particular, speakers will explore the translation of neuroscience knowledge into more precise and clinically relevant surrogate markers of clinical response. Specific topics will include the integration of biochemical, neuroimaging, electrophysiologic, and pharmacogenomic markers into clinical trials for new antidepressants.

**Course Directors**

**Maurizio Fava, MD**

**George I. Papakostas, MD**

**Steven D. Targum, MD**

**Agenda**

**April 24th, 2006**

---

<b>9:00 – 9:30</b>	<b>Registration and Coffee</b>
<b>9:30 – 10:15</b>	<b>Animal Models of Depression and Drug Development</b> <i>William A. Carlezon, PhD</i>
<b>10:15 – 10:45</b>	<b>Research of study design</b> <i>George I. Papakostas, MD</i>
<b>10:45 – 11:00</b>	<b>Coffee Break</b>
<b>11:00 – 11:30</b>	<b>Novel study designs</b> <i>Maurizio Fava, MD</i>
<b>11:30 – 12:00</b>	<b>Issues in clinical trial implementation</b> <i>Steven D. Targum, MD</i>
<b>12:00 – 12:30</b>	<b>Open Discussion</b>
<b>12:30 – 1:30</b>	<b>Lunch</b>
<b>1:30 – 2:15</b>	<b>Translating Translational Medicine</b> <i>Earl Giller, MD, PhD</i>
<b>2:15 – 2:45</b>	<b>PET and fMRI</b> <i>Darin D. Dougherty, M.D.</i>
<b>2:45 – 3:00</b>	<b>Coffee Break</b>
<b>3:00 – 3:30</b>	<b>QEEG</b> <i>Dan V. Iosifescu, MD</i>
<b>3:30 – 4:00</b>	<b>Genetics</b> <i>Roy H. Perlis, MD</i>
<b>4:00 – 4:30</b>	<b>Open Discussion</b>
<b>4:30 – 5:15</b>	<b>Collaborations for new translational models of signal detection</b> <i>William Z. Potter, MD</i>

---

**Faculty**

**William A. Carlezon, PhD**, Director, Behavioral Genetics Laboratory, McLean Hospital; Associate Professor of Psychiatry and Neuroscience, Harvard Medical School

**Darin D. Dougherty, MD**, Assistant Director of the Psychiatric Neuroimaging Program, Massachusetts General Hospital; Assistant Professor of Psychiatry, Harvard Medical School

**Maurizio Fava, MD**, Associate Chief of Psychiatry for Clinical Research, Director, Depression Clinical and Research Program, Massachusetts General Hospital; Professor of Psychiatry, Harvard Medical School

**Earl Giller, MD, PhD**, Vice President, Clinical Development, Marinus Pharmaceuticals, Inc

**Dan V. Iosifescu, MD**, Director of Neurophysiology Studies, Depression Clinical and Research Program, Massachusetts General Hospital; Assistant Professor of Psychiatry, Harvard Medical School

**George I. Papakostas, MD**, Director, Neuroendocrine and Metabolic Studies, Depression Clinical and Research Program, Massachusetts General Hospital; Assistant Professor of Psychiatry, Harvard Medical School

**Roy H. Perlis, MD**, Director, Pharmacogenomics Research, Depression and Bipolar Research Programs, Massachusetts General Hospital; Assistant Professor of Psychiatry, Harvard Medical School

**William Z. Potter, MD, PhD**, Vice President, Clinical Neuroscience, Merck & Co., Inc.

**Steven D. Targum, MD**, Consultant in Psychiatry, Massachusetts General Hospital; Clinical Lecturer, Harvard Medical School